Table 3.

Patients at high risk of TLS who could benefit by rasburicase

Tumor factors	Patients factors	Biochemical factors
High tumor burden	Hyperleukocytosis	High uric acid levels
High tumor growth rate	Pre-existing renal impairment	High LDH levels
High sensitivity to chemotherapy, especially during early treatment phase	Dehydration	High phosphoremia levels
Advanced stage of tumor	Poly-pharmacology	Low pH of urine
Kind of tumor (haematological malignancies more than solid tumors)		High creatinine levels
Lymphoma infiltration of kidney
Use of monoclonal antibodies and targeted therapies